BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 26312706)

  • 21. Synchronous gastric and sebaceous cancers, a rare manifestation of MLH1-related Muir-Torre syndrome.
    Svec J; Schwarzová L; Janošíková B; Stekrová J; Mandys V; Kment M; Vodička P
    Int J Clin Exp Pathol; 2014; 7(8):5196-202. PubMed ID: 25197397
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patients with a new-onset cutaneous sebaceous neoplasm following immunosuppression should be evaluated for Muir-Torre syndrome with germline mismatch repair gene mutation analysis: case reports.
    Cohen PR; Kurzrock R
    Dermatol Online J; 2024 Mar; 30(1):. PubMed ID: 38762859
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Muir-Torre syndrome: sebaceous carcinoma concurrent with colon cancer in a kidney transplant recipient; a case report.
    Tomonari M; Shimada M; Nakada Y; Yamamoto I; Itoh M; Koike Y; Kobayashi A; Miki J; Yamada H; Kimura T; Saito S; Sugano K; Sekine S; Yamamoto H; Asahina A; Yokoo T
    BMC Nephrol; 2019 Oct; 20(1):394. PubMed ID: 31664942
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An Intrapatient Concordance Study of Mismatch Repair Protein Immunohistochemical Staining Patterns in Patients With Muir-Torre Syndrome.
    Nguyen CV; Gaddis KJ; Stephens MR; Seykora JT; Chu EY
    JAMA Dermatol; 2020 Jun; 156(6):676-680. PubMed ID: 32267475
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Muir-Torre syndrome-associated pleomorphic liposarcoma arising in a previous radiation field.
    Yozu M; Symmans P; Dray M; Griffin J; Han C; Ng D; Parry S; Wong K
    Virchows Arch; 2013 Mar; 462(3):355-60. PubMed ID: 23299928
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiple benign adnexal tumours: Anything but benign.
    McCarthy RL; Thomas CL; Isaacs F
    Australas J Dermatol; 2019 Aug; 60(3):234-236. PubMed ID: 30671930
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DNA mismatch repair defects and microsatellite instability status in periocular sebaceous carcinoma.
    Rajan Kd A; Burris C; Iliff N; Grant M; Eshleman JR; Eberhart CG
    Am J Ophthalmol; 2014 Mar; 157(3):640-7.e1-2. PubMed ID: 24321472
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Muir-Torre syndrome: a case of unusual coexisting genetic mutations.
    Cino D; Drumm C; Sheahan K; D'Arcy C; Nolan N; Hoti E; Winter D; O'Duffy F; Dolan R; Moriarty B
    Clin Exp Dermatol; 2022 Mar; 47(3):602-604. PubMed ID: 34762321
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sebaceous adenomas of the eyelid and Muir-Torre Syndrome.
    Jagan L; Zoroquiain P; Bravo-Filho V; Logan P; Qutub M; Burnier MN
    Br J Ophthalmol; 2015 Jul; 99(7):909-13. PubMed ID: 25595178
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Value of MLH1 and MSH2 mutations in the appearance of Muir-Torre syndrome phenotype in HNPCC patients presenting sebaceous gland tumors or keratoacanthomas.
    Ponti G; Losi L; Pedroni M; Lucci-Cordisco E; Di Gregorio C; Pellacani G; Seidenari S
    J Invest Dermatol; 2006 Oct; 126(10):2302-7. PubMed ID: 16826164
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MSH6, Past and Present and Muir-Torre Syndrome-Connecting the Dots.
    Mahalingam M
    Am J Dermatopathol; 2017 Apr; 39(4):239-249. PubMed ID: 28323777
    [TBL] [Abstract][Full Text] [Related]  

  • 32. "Second hit" in sebaceous tumors from Muir-Torre patients with germline mutations in MSH2: allele loss is not the preferred mode of inactivation.
    Kruse R; Rütten A; Hosseiny-Malayeri HR; Bisceglia M; Friedl W; Propping P; Ruzicka T; Mangold E
    J Invest Dermatol; 2001 Mar; 116(3):463-5. PubMed ID: 11231323
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Germline Testing of Mismatch Repair Genes Is Needed in the Initial Evaluation of Patients With Muir-Torre Syndrome-Associated Cutaneous Sebaceous Neoplasms: A Case Series.
    Cohen PR; Kurzrock R
    Cureus; 2023 Jan; 15(1):e33975. PubMed ID: 36824550
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Muir-Torre syndrome.
    Navi D; Wadhera A; Fung MA; Fazel N
    Dermatol Online J; 2006 Sep; 12(5):4. PubMed ID: 16962019
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and Molecular Features of Skin Malignancies in Muir-Torre Syndrome.
    Simic D; Dummer R; Freiberger SN; Ramelyte E; Barysch MJ
    Genes (Basel); 2021 May; 12(5):. PubMed ID: 34065301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glioblastoma multiforme in the Muir-Torre syndrome.
    Binder ZA; Johnson MW; Joshi A; Hann CL; Griffin CA; Olivi A; Riggins GJ; Gallia GL
    Clin Neurol Neurosurg; 2011 Jun; 113(5):411-5. PubMed ID: 21288634
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reticulated acanthoma with sebaceous differentiation: another sebaceous neoplasm associated with Muir-Torre syndrome?
    Shon W; Wolz MM; Newman CC; Bridges AG
    Australas J Dermatol; 2014 Nov; 55(4):e71-3. PubMed ID: 23651324
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Muir-Torre syndrome and recent updates on screening guidelines: The link between colorectal tumors and sebaceous adenomas in unusual locations.
    Shaker N; Shaker N; Abid A; Shah S; Shakra RA; Sangueza OP
    J Surg Oncol; 2023 Dec; 128(8):1380-1384. PubMed ID: 37706607
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Muir-Torre syndrome: rare association with duodenal carcinoma].
    Bacha D; Deschamps L; Sauvanet A; Couvelard A
    Ann Pathol; 2009 Dec; 29(6):495-8. PubMed ID: 20005439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Review of the current medical literature and assessment of current utilization patterns regarding mismatch repair protein immunohistochemistry in cutaneous Muir-Torre syndrome-associated neoplasms.
    Lee JB; Litzner BR; Vidal CI
    J Cutan Pathol; 2017 Nov; 44(11):931-937. PubMed ID: 28749576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.